HK1072361B - Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis
- Google Patents
Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis
Download PDF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 赛诺菲 安万特filedCritical赛诺菲 安万特
Priority claimed from PCT/EP2003/000696external-prioritypatent/WO2003063881A1/en
Publication of HK1072361A1publicationCriticalpatent/HK1072361A1/en
Publication of HK1072361BpublicationCriticalpatent/HK1072361B/en
Dosis von 2,5 mg des Pentasaccharids Methyl-O-(2,3,4-tri-O-methyl-6-O-sulfo-α-D-glucopyranosyl)-(1 → 4)-O-(2,3-di-O-methyl-β-D-glucopyranosyluronsäure)-(1 → 4)-O-(2,3,6-tri-O-sulfo-α-D-glucopyranosyl)-(1 → 4)-O-(2,3-di-O-methyl-α-L-idopyranosyluronsäure)-(1 → 4)-2,3,6-tri-O-sulfo-α-D-glucopyranosyl oder eines pharmazeutisch verträglichen Salzes davon zur Verwendung bei der Therapie für eine Verabreichung einmal pro Woche.
Dosis nach Anspruch 1, worin das Pentasaccharid in Form seines Nonanatriumsalzes (SanOrg34006) vorliegt.
Verwendung einer Dosis von 2,5 mg des Pentasaccharids Methyl-O-(2,3,4-tri-O-methyl-6-O-sulfo-α-D-glucopyranosyl)-(1 → 4)-O-(2,3-di-O-methyl-β-D-glucopyranosyluronsäure)-(1 → 4)-O-(2,3,6-tri-O-sulfo-α-D-glucopyranosyl)-(1 → 4)-O-(2,3-di-O-methyl-α-L-idopyranosyluronsäure) - (1 → 4)-2,3,6-tri-O-sulfo-α-D-glucopyranosyl oder eines pharmazeutisch verträglichen Salzes davon zur Herstellung eines einmal pro Woche zu verabreichenden Arzneimittels für die Behandlung und/oder sekundäre Prophylaxe von venösen thromboembolischen Ereignissen bei Patienten mit tiefer venöser Thrombose.
Verwendung nach Anspruch 1, wobei das Pentasaccharid in Form seines Nonanatriumsalzes (SanOrg34006) vorliegt.
HK05103708.2A2002-01-292003-01-23Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis
HK1072361B
(en)
Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery
Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine
Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II